A randomized double-blind placebo-controlled trial of a multi-strain probiotic in treatment of symptomatic uncomplicated diverticular disease

Inflammopharmacology

Volumn 25, Issue 5, 2017, Pages 499-509

  Kvasnovsky, Charlotte L ^a,b,c   Bjarnason, Ingvar ^c   Donaldson, Ana Nora ^d   Sherwood, Roy A ^c   Papagrigoriadis, Savvas ^c  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d STONY BROOK UNIVERSITY   (United States)

Author keywords

Diverticular disease; Microbiota; Probiotics

Indexed keywords

CALGRANULIN; PLACEBO; PROBIOTIC AGENT; SYMPROVE;

ABDOMINAL BLEEDING; ABDOMINAL DISEASE; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BACKACHE; BACTERIAL STRAIN; BLOATING; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIVERTICULOSIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; DYSPEPSIA; DYSURIA; ENTERITIS; FEMALE; HALITOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCORRHEA; NAUSEA; PAIN ASSESSMENT; PAIN SEVERITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM ASSESSMENT; TREATMENT DURATION; VAGINA DISCHARGE; VOMITING; WEAKNESS;

EID: 85019575656     PISSN: 09254692     EISSN: 15685608     Source Type: Journal    
DOI: 10.1007/s10787-017-0363-y     Document Type: Article

References (34)

1. Angriman I, Scarpa M, Castagliuolo I (2014) Relationship between pouch microbiota and pouchitis following restorative proctocolectomy for ulcerative colitis. World J Gastroenterol 20:9665–9674
2. Boostrom SY, Wolff BG, Cima RR, Merchea A, Dozois EJ, Larson DW (2012) Uncomplicated diverticulitis, more complicated than we thought. J Gastrointest Surg 16:1744–1749
3. Cohen E, Fuller G, Bolus R, Modi R, Vu M, Shahedi K et al (2013) Increased risk for irritable bowel syndrome after acute diverticulitis. Clin Gastroenterol Hepatol 11:1614–1619
4. Cuomo R, Barbara G, Andreozzi P, Bassotti GC, Asetti T, Grassini M et al (2013) Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. Eur J Clin Invest 43:1147–1155
5. Dai C, Jiang M (2012) The incidence and risk factors of post-infectious irritable bowel syndrome: a meta-analysis. Hepatogastroenterology 59:67–72
6. Daniels L, Philipszoon LE, Boermeester MA (2014) A hypothesis: important role for gut microbiota in the etiopathogenesis of diverticular disease. Dis Colon Rectum 57:539–543
7. Hall JF (2014) The microbiome and diverticulitis: a new target for medical therapy? Dis Colon Rectum 57:544–545
8. Hobson KG, Roberts PL (2004) Etiology and pathophysiology of diverticular disease. Clin Colon Rectal Surg 17:147–153
9. Hold GL, Smith M, Grange C, Watt ER, El-Omar EM, Mukhopadhya I (2014) Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? World J Gastroenterol 20:1192–1210
10. Humes DJ, Simpson J, Smith J, Sutton P, Zaitoun A, Bush D et al (2012) Visceral hypersensitivity in symptomatic diverticular disease and the role of neuropeptides and low grade inflammation. Neurogastroenterol Motil 24:318-e163
11. Kvasnovsky CL, Papagrigoriadis S (2015) Symptoms in patients with diverticular disease should not be labelled as IBS. Int J Colorectal Dis 30:995
12. Kvasnovsky CL, Bjarnason I, Papagrigoriadis S (2015) What colorectal surgeons should know about probiotics: a review. Colorectal Dis 17:840–848
13. Lab tests online (2015) https://labtestsonline.org/understanding/analytes/gfr/tab/test/. 30 July 2015
14. Lahner E, Esposito G, Zullo A, Hassan C, Cannaviello C, Paolo MC et al (2012) High-fibre diet and Lactobacillus paracasei B21060 in symptomatic uncomplicated diverticular disease. World J Gastroenterol 18:5918–5924
15. Marranzino G, Villena J, Salva S, Alvarez S (2012) Stimulation of macrophages by immunobiotic Lactobacillus strains: influence beyond the intestinal tract. Microbiol Immunol 56(11):771–781
16. Marshall JK, Thabane M, Borgaonkar MR, James C (2007) Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol 5:457–460
17. Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM, Walkerton Health Study Investigators (2010) Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut 59:605–611
18. Moher D, Schulz KF, Altman DG, CONSORT group (Consolidated Standards of Reporting Trials) (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 134:657–662
19. Morken MH, Lind RA, Valeur J, Wilhelmsen I, Berstad A (2009) Subjective health complaints and quality of life in patients with irritable bowel syndrome following Giardia lamblia infection: a case control study. Scand J Gastroenterol 44:308–313
20. Neal KR, Hebden J, Spiller R (1997) Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 314:779–782
21. Painter NS, Burkitt DP (1971) Diverticular disease of the colon: a deficiency disease of Western civilization. Br Med J 2:450–454
22. Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ et al (2012) Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 143:1179–1187
23. Roland M, Torgerson DJ (1998) Understanding controlled trials: what are pragmatic trials? BMJ 316(7127):285 (Clinical research ed)
24. Schwille-Kiuntke J, Enck P, Zendler C, Krieg M, Polster AV, Klosterhalfen S et al (2011) Postinfectious irritable bowel syndrome: follow-up of a patient cohort of confirmed cases of bacterial infection with Salmonella or Campylobacter. Neurogastroenterol Motil 23:479–488
25. Sisson G, Ayis S, Sherwood RA, Bjarnason I (2014) Randomised clinical trial: a liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome–a 12 week double-blind study. Aliment Pharmacol Ther 40:51–60
26. Sisson G, Hayee B, Bjarnason I (2015) Assessment of a multi strain probiotic (Symprove) in IBD. Gastroenterology 148:S-531
27. Spiller R (2012) Is it diverticular disease or is it irritable bowel syndrome? Dig Dis 30:64–69
28. Spiller R (2014) New thoughts on the association between diverticulosis and irritable bowel syndrome. Am J Gastroenterol 109:1906–1908
29. Stollman N, Magowan S, Shanahan F, Quigley EM, DIVA Investigator Group (2013) A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. J Clin Gastroenterol 47(7):621–629. doi:10.1097/MCG0b013e31828003f6
30. Tibble JSG, Foster R, Sherwood R, Fagerhol M, Bjarnason I (2001) Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 49:402–408
31. Tursi A, Brandimarte G, Elisei W, Picchio M, Forti G, Pianese G et al (2013) Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease–a double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther 38:741–751
32. Tursi A, Elisei W, Picchio M, Brandimarte G (2014) Increased faecal calprotectin predicts recurrence of colonic diverticulitis. Int J Colorectal Dis 29:931–935
33. Wolff BG, Boostrom SY (2012) Prophylactic resection, uncomplicated diverticulitis, and recurrent diverticulitis. Dig Dis 30:108–113
34. Yamada EI, Namori M, Uchida E, Tanida E, Izumi M, Takeshita K et al (2014) Association between the location of diverticular disease and the irritable bowel syndrome: a multicenter study in Japan. Am J Gastroenterol 109:1900–1905